Shenzhen Hepalink Pharmaceutical Group Balance Sheet Health
Financial Health criteria checks 5/6
Shenzhen Hepalink Pharmaceutical Group has a total shareholder equity of CN¥12.2B and total debt of CN¥4.2B, which brings its debt-to-equity ratio to 34.8%. Its total assets and total liabilities are CN¥18.1B and CN¥5.9B respectively.
Key information
34.8%
Debt to equity ratio
CN¥4.25b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥3.08b |
| Equity | CN¥12.21b |
| Total liabilities | CN¥5.91b |
| Total assets | CN¥18.12b |
Recent financial health updates
Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt
Oct 07
Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt
Jun 12Recent updates
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) Business Is Trailing The Industry But Its Shares Aren't
Dec 06Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt
Oct 07Some Shareholders Feeling Restless Over Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) P/S Ratio
Aug 22Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt
Jun 12Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) 26% Price Boost Is Out Of Tune With Revenues
May 06Financial Position Analysis
Short Term Liabilities: 002399's short term assets (CN¥10.4B) exceed its short term liabilities (CN¥4.3B).
Long Term Liabilities: 002399's short term assets (CN¥10.4B) exceed its long term liabilities (CN¥1.6B).
Debt to Equity History and Analysis
Debt Level: 002399's net debt to equity ratio (9.6%) is considered satisfactory.
Reducing Debt: 002399's debt to equity ratio has reduced from 91.2% to 34.8% over the past 5 years.
Debt Coverage: 002399's debt is well covered by operating cash flow (57.1%).
Interest Coverage: Insufficient data to determine if 002399's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 07:26 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lei Tian | AJ Securities Co., Ltd |
| Peng Yan | Changjiang Securities Co. LTD. |
| Diandian Li | China Merchants Securities Co. Ltd. |